31 December 2006 in Acta Obstetricia et Gynecologica Scandinavica
Background. The purpose of this study was to evaluate the predictive value of preoperative serum CA‐125 levels in the assessment of disease extent and clinical outcome of endometrial cancer. Method. This retrospective study evaluated 92 women with pathologically proven endometrial carcinoma scheduled for treatment that had preoperative serum CA‐125 levels between January 1999 and February 2006. The association of preoperative serum CA‐125 with a variety of histopathologic factors was evaluated. Statistical analysis was performed using φ2/Fisher's exact test and a logistic regression. Survival was studied with the Kaplan–Meier method and Cox regression models. Results. Elevated serum CA‐125 levels were significantly correlated with advanced‐stage disease (p<0.001), lymph node metastases (p<0.001), increased depth of myometrial invasion (p = 0.001), and positive peritoneal cytology (p = 0.026). Multivariate analyses using logistic regression showed that lymph node metastases had the most significant effect on the elevation of preoperative serum CA‐125 levels (p = 0.004). Patients with a serum CA‐125 ≤28.5 U/ml had a significantly better five‐year disease‐free survival than those with an elevated level in this study: 85.6% versus 60.0% (p = 0.004). Conclusions. The preoperative serum CA‐125 level appears to be a significant independent predictor of lymph node metastasis and prognosis after surgical intervention. Therefore, preoperative serum CA‐125 may be a useful tool, in the clinical setting, for optimal individualized patient management.
7 May 2019 in Journal of Ovarian Research
To evaluate impact of germline BRCA mutational status on prognosis in patients with advanced ovarian cancer. A total of 128 patients diagnosed with FIGO stage III-IV high-grade serous ovarian cancer (HGSOC) between 2008 and 2017 and underwent BRCA1/2 gene testing at the time of or within two years from cancer diagnosis were included in this study. We compared patients’ clinicopathological characteristics and survival outcomes after primary treatment according to germline BRCA mutational status. Treatment-related factors that might affect patients’ survival outcome were also investigated. Germline BRCA1/2 mutations were observed in 51 women (39.8%). There were no differences in age and serum CA-125 levels at the time of HGSOC diagnosis, use of neoadjuvant chemotherapy (NAC), extent of debulking surgery, and overall survival (OS) between the BRCA mutation and wild-type BRCA groups. In contrast, the BRCA mutation group displayed longer progression-free survival (PFS) (median, 22.9 vs. 16.9 months, P = 0.001). Multivariate analyses identified germline BRCA1/2 mutation as an independent favorable prognostic factor for PFS (adjusted HR, 0.502; 95% CI, 0.318–0.795; P = 0.003). In the wild-type BRCA group, patients who received NAC as the primary treatment had shorter PFS compared to those who received primary debulking surgery (PDS) (median, 14.2 vs. 16.9 months, P = 0.003). However, in the BRCA mutation group, PFS did not differ between the NAC and PDS groups (P = 0.082). In advanced-stage HGSOC, patients with germline BRCA1/2 mutations have better prognosis with longer PFS than those lacking BRCA mutations. Prognosis after NAC was different according to the BRCA mutational status.
8 January 2008 in European Journal of Nuclear Medicine and Molecular Imaging
1 January 2016 in Journal of Gynecologic Oncology
Chung HH, et al. J Gynecol Oncol. 2015 Dec;27(2):e15. https://doi.org/10.3802/jgo.2016.27.e15
27 April 2016 in European Radiology
1 January 2017 in Journal of Gynecologic Oncology
Lim MC, et al. J Gynecol Oncol. 2017 Mar;28(3):e22. https://doi.org/10.3802/jgo.2017.28.e22